| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
in00005773530 |
| 005 |
20260327180133.3 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
241103s2024 enk ob 000 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|e rda
|e pn
|c SFB
|d OCLCO
|d OCLCQ
|d OCLCL
|
| 020 |
|
|
|a 0443293260
|
| 020 |
|
|
|a 9780443293269
|
| 020 |
|
|
|a 0443293279
|
| 020 |
|
|
|a 9780443293276
|
| 035 |
|
|
|a (OCoLC)1446806591
|
| 050 |
|
4 |
|a RS403
|b .P764 2024
|
| 082 |
0 |
4 |
|a 615.19
|2 23
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Profiles of Drug Substances, Excipients, and Related Methodology /
|c edited by Abdulrahman Al-Majed.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a London, England :
|b Academic Press,
|c [2024]
|
| 264 |
|
4 |
|c ©2024
|
| 300 |
|
|
|a 1 online resource (454 p.).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Profiles of Drug Substances, Excipients and Related Methodology Series ;
|v Volume 49
|
| 520 |
|
|
|a Profiles of Drug Substances, Excipients, and Related Methodology, Volume 49 provides timely and pertinent information on a variety of timely topics, including Physical Profiles of Drug Substances and Excipients; Analytical Profiles of Drug Substances and Excipients; ADME Profiles of Drug Substances and Excipients; Methodology Related to the Characterization of Drug Substances and Excipients; and Methods of Chemical Synthesis. In addition, it includes comprehensive profiles of five drug compounds: Deferasirox, Duvelisib, Regorafenib, Ponatinib and Avanafil. Finally, the book contains a chapter on Regulation and Standardization of Herbal Drugs: Current status, Limitation, Challenge's, and Future Prospectives.
|
| 505 |
0 |
|
|a Front Cover -- Series Page -- Title Page -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Deferasirox: A comprehensive drug profileDeferasirox: A comprehensive drug profile -- 1 Description -- 1.1 History -- 1.2 Nomenclature -- 1.2.1 Systemic chemical name -- 1.2.2 Nonproprietary names -- 1.2.3 Proprietary names -- 1.3 Formulae -- 2 Mode of action -- 3 Pharmacokinetics -- 4 Indications -- 5 Synthesis -- 6 Physical characteristics -- 6.1 Solubility -- 6.2 Dissociation constant -- 6.3 Optical activity -- 6.4 Density -- 6.5 Partition coefficient -- 6.6 Melting behavior -- 6.7 Lattice analysis by X-ray powder diffraction -- 6.8 Thermal analysis -- 6.9 FTIR spectroscopy -- 6.10 NMR spectroscopic analysis -- 7 Methods of analysis -- 7.1 Reversed phase-high performance liquid chromatography (RP-HPLC) method -- 7.2 Liquid chromatography combined with tandem mass spectrometry (LC-MS/MS) methods -- 7.3 Spectrophotometric methods -- 7.4 Fluorescence methods -- Acknowledgment -- References -- Chapter Two: Duvelisib: A comprehensive profile -- 1 Description -- 1.1 Nomenclature -- 1.1.1 Systemic chemical names [1] -- 1.1.2 Nonproprietary names [1] -- 1.2 Formulae -- 1.2.1 Empirical formula -- 1.2.2 Structural formula -- 1.3 Elemental composition -- 1.4 Appearance [2,3] -- 1.5 Physicochemical properties [4,5] -- 2 Uses and applications -- 3 Methods of preparation -- 4 Spectroscopic analysis -- 4.1 Ultraviolet-visible spectroscopy -- 4.2 Fluorescence spectroscopy -- 4.3 Fourier-transform infrared absorption spectroscopy -- 4.4 1H-nuclear magnetic resonance spectrometry -- 4.5 Mass spectrometry -- 5 Thermogravimetric analysis -- 6 Methods of analysis -- 6.1 Compendial method -- 6.2 Spectroscopic methods -- 6.2.1 Ultraviolet-visible spectrophotometry -- 6.2.2 Spectrofluorometry -- 6.3 Chromatographic methods -- 7 Pharmacological properties.
|
| 505 |
8 |
|
|a 7.1 Mechanism of action -- 7.2 Pharmacokinetics -- 8 Dosing information -- 8.1 Dosage forms and administration -- 8.2 Contraindications -- 8.3 Adverse reactions -- 8.4 Warning and precautions -- 8.4.1 Infections -- 8.4.2 Diarrhea or colitis -- 8.4.3 Cutaneous reactions -- 8.4.4 Pneumonitis -- 8.4.5 Hepatotoxicity -- 8.4.6 Neutropenia -- 8.4.7 Embryo-fetal toxicity -- 8.5 Use in specific population -- 8.5.1 Pregnancy -- 8.5.2 Breastfeeding -- 8.5.3 Pediatric use -- 8.5.4 Hepatic impairment -- 8.5.5 Renal impairment -- References -- Chapter Three: Regorafenib: A comprehensive drug profile -- 1 Description -- 1.1 Nomenclature -- 1.1.1 Systematic chemical names [1] -- 1.1.2 Nonproprietary names [1] -- 1.1.3 Proprietary names [1] -- 1.2 Formulae [1] -- 1.2.1 Empirical formula, molecular weight, CAS number -- 1.2.2 Structural formula [1] -- 1.2.3 Simplified molecular input line entry system (SMILES) [1] -- 1.2.4 The IUPAC international chemical identifier (InChI) [1] -- 1.3 Elemental analysis -- 1.4 Appearance [2] -- 2 Physical characteristics -- 2.1 Ionization constants -- 2.2 Solubility characteristics -- 2.3 Partition coefficients -- 2.4 Crystallographic properties -- 2.4.1 X-ray powder diffraction pattern -- 2.5 Thermal methods of analysis -- 2.5.1 Melting behavior -- 2.5.2 Differential scanning calorimetry (DSC) -- 2.6 Spectroscopic identification -- 2.6.1 UV/VIS spectroscopy -- 2.6.2 Vibrational spectroscopy -- 2.7 Nuclear magnetic resonance spectrometry -- 2.7.1 1H NMR spectrum -- 2.7.2 13C NMR spectrum -- 2.8 Mass spectrometry -- 3 Methods of preparation -- 4 Methods of analysis -- 4.1 Electrochemical methods of analysis -- 4.2 Spectrophotometric methods of analysis -- 4.3 Chromatographic methods of analysis -- 5 Pharmacology -- 5.1 Pharmacokinetics -- 5.1.1 Absorption -- 5.1.2 Distribution -- 5.1.3 Elimination -- 5.1.4 Metabolism.
|
| 505 |
8 |
|
|a 5.1.5 Excretion -- 5.2 Pharmacological effects -- 5.3 Drug-drug interactions -- References -- Chapter Four: Ponatinib: A comprehensive drug profile -- 1 General information -- 1.1 Nomenclature -- 1.1.1 Systematic chemical names -- 1.1.1.1 Ponatinib base [1] -- 1.1.1.2 Ponatinib hydrochloride -- 1.1.2 Non-proprietary names (generic names) -- 1.1.3 Proprietary names (brand Names) -- 1.2 Formulae -- 1.2.1 Empirical formula, molecular weight, and CAS number -- 1.2.2 Structural formula -- 1.3 Elemental analysis -- 1.4 Appearance -- 2 Physical characteristics -- 2.1 Dissociation constants -- 2.2 Solubility characteristics -- 2.3 Partition coefficients -- 2.4 Crystallographic properties -- 2.4.1 Single crystal structure [9] -- 2.4.2 X-ray powder diffraction pattern -- 2.5 Thermal gravimetric analysis (TGA) -- 2.6 Spectroscopy -- 2.6.1 Ultraviolet spectroscopy -- 2.6.2 Nuclear magnetic resonance spectrometry -- 2.6.2.1 1H NMR spectrum -- 2.6.2.2 13C NMR spectrum -- 2.6.3 Infrared spectroscopy -- 2.7 Mass spectrometry -- 3 Uses and applications -- 4 Stability -- 5 Preparation of ponatinib -- 6 Impurities -- 7 Reported methods of analysis -- 7.1 Electrochemical approach -- 7.2 Spectroscopic methods of analysis -- 7.2.1 Spectrofluorimetric method -- 7.2.2 Stimulated raman scattering (SRS) microscopy -- 7.3 Chromatographic methods of analysis -- 7.4 Immunoassay -- 8 Clinical pharmacology -- 8.1 Mechanism of action -- 8.2 Pharmacokinetics -- 8.2.1 Absorption -- 8.2.2 Distribution -- 8.2.3 Metabolism -- 8.2.4 Excretion -- 8.2.5 Special populations -- 8.3 Pharmacodynamics -- 8.4 Dosage -- 8.5 Adverse effects -- 8.6 Drug interactions -- References -- Chapter Five: Avanafil: A comprehensive drug profile -- 1 Description -- 1.1 Nomenclature -- 1.1.1 IUPAC names -- 1.1.1.1 Avanafil -- 1.1.1.2 Avanafil dibenzenesulfonate -- 1.1.2 Nonproprietary name.
|
| 505 |
8 |
|
|a 1.1.3 Proprietary names -- 1.2 Formulae -- 1.2.1 Empirical formula, molecular weight, and CAS no -- 1.2.2 Structural formula -- 1.3 Elemental analysis -- 2 Methods of preparation of avanafil -- 3 Physical characteristics -- 3.1 Physical appearance -- 3.2 Specific rotation -- 3.3 Melting point -- 3.4 Dissociation constant -- 3.5 Solubility and partition coefficient -- 3.6 Stability -- 3.7 Crystallographic properties -- 3.8 Thermal analysis -- 3.9 Spectroscopy -- 3.9.1 UV/Vis spectroscopy -- 3.9.2 Spectrofluorimetric method -- 3.9.3 Infrared spectroscopy -- 3.9.3.1 Mass spectroscopy -- 3.9.4 NMR spectroscopy -- 3.9.4.1 1H NMR spectroscopy -- 3.9.5 13C NMR spectroscopy -- 4 Methods of analysis -- 4.1 Compendial method -- 4.2 Reported methods of analysis -- 4.2.1 Electrochemical methods -- 4.2.2 Spectroscopic methods -- 4.2.2.1 Colorimetric method -- 4.2.2.2 Spectrophotometry method -- 4.2.2.3 Spectrofluorimetric method -- 4.2.3 Capillary electrophoresis -- 4.2.4 Chromatography -- 4.2.4.1 High-performance thin-layer chromatography (HPTLC) methods -- 4.2.4.2 High-performance liquid chromatography methods -- 4.2.4.3 Liquid chromatography-tandem mass spectrometric methods (LC/MS) -- 4.2.4.4 Gas chromatography-mass spectrometry (GC/MS) -- 5 Stability -- 6 Clinical pharmacology of avanafil -- 6.1 Mechanism of action -- 6.2 Pharmacokinetics -- 6.2.1 Absorption -- 6.2.2 Distribution -- 6.2.3 Metabolism -- 6.2.4 Elimination -- 6.2.5 Special populations -- 6.3 Dosage and administration -- 6.4 Drug interactions -- 6.5 Adverse effects -- 6.6 Effects on the body -- References -- Chapter Six: Regulation and standardization of herbal drugs: Current status, limitation, challenge's and future prospective -- 1 Introduction -- 2 Regulation of herbal drugs -- 2.1 US Food and Drug Administration (FDA) -- 2.2 European Medicines Agency (EMA).
|
| 505 |
8 |
|
|a 2.3 Pharmaceutical and Medical Devices Agency (PMDA) of Japan -- 2.4 Ministry of Health and Welfare Taiwan, Republic of China -- 2.5 Chinese Medicine Regulatory Office, Department of Health, The Government of Hong Kong Special Administrative Region -- 2.6 Indonesian National Agency of Drug and Food Control (BPOM-RI) -- 2.7 Summary and discussions -- 3 Standardization of herbal drugs: current criteria and limitations -- 3.1 Sampling and identification -- 3.2 Quantitative determination -- 3.3 Specific tests -- 3.4 Microbial quality tests -- 3.5 Summary and discussion -- 4 Challenges and future perspective of HD standardization methods -- 4.1 Qualitative method (identification) -- 4.2 Quantitative analysis and limit tests -- 5 Summary and recommendations -- Acknowledgments -- References -- Cumulative index -- Back Cover.
|
| 588 |
|
|
|a Description based on print version record.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 650 |
|
0 |
|a Pharmaceutical chemistry.
|
| 650 |
|
2 |
|a Chemistry, Pharmaceutical
|
| 650 |
|
6 |
|a Chimie pharmaceutique.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Al-Majed, Abdulrahman,
|e editor.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 830 |
|
0 |
|a Profiles of drug substances, excipients, and related methodology ;
|v Volume 49.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/bookseries/18715125/49
|z Connect to the full text of this electronic book
|t 0
|
| 936 |
|
|
|a BATCHLOAD
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i ec8f9bc4-8f9d-4bac-8dfb-e35a9b4de63d
|s 872cd5ae-e360-4cd1-914f-2a3aa9fc1820
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RS403 .P764 2024
|h Library of Congress classification
|
| 998 |
f |
f |
|a RS403 .P764 2024
|t 0
|l Available Online
|